Scientists from Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates (ADC) comprising antibodies targeting HER2 bound to an eribulin derivative through a linker reported to be useful for the treatment of cancer.
The development of KRAS G12D inhibitors has proven challenging to date and, different from anti-KRAS G12C strategies, no compound targeting KRAS G12D mutation has been approved so far.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified sodium channel protein type 10 subunit α (Nav1.8) channel blockers reported to be useful for the treatment of treatment of pain, Charcot-Marie-Tooth disease, urinary incontinence, multiple sclerosis and arrhythmia.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an EGFR targeting moiety reported to be useful for the treatment of cancer particularly, non-small-cell lung cancer (NSCLC).
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed HER2 (erbB2) and/or HER2 (erbB2) mutant inhibitors reported to be useful for the treatment of cancer.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described fused heterocyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors.
Cyclin-dependent kinase 7 (CDK7) regulates both cell cycle and global transcription and is a validated therapeutic target in cancer. Researchers from Shanghai Hengrui Pharmaceutical Co. Ltd. reported on the discovery and preclinical evaluation of SHR-5428, a noncovalent CDK7 inhibitor.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of chronic obstructive pulmonary disease, fibrosis, psoriasis, erectile dysfunction, multiple sclerosis, heart failure, overactive bladder and neuropathic pain, among others.
